Low molecular weight heparin-loaded polymeric nanoparticles: formulation,characterization, and release characteristics

The aim of the present work was to investigate the preparation of low molecular weight heparin (LMWH) nanoparticles (NP) as potential oral heparin carriers. The NP were formulated using an ultrasound probe by water-in-oil-in-water (w/o/w) emulsification and solvent evaporation with two biodegradable polymers [poly-epsilon-caprolactone, PCL and poly(D,L-lactic-co-glycolic acid) 50/50, PLGA] and two non-biodegradable positively charged polymers (Eudragit RS and RL) used alone or in combination. The mean diameter of LMWH-loaded NP ranged from 240 to 490 nm and was dependent on the reduced viscosity of the polymeric organic solution. The surface potential of LMWH NP prepared with Eudragit polymers used alone or blended with PCL and PLGA was changed dramatically from strong positive values obtained with unloaded NP to negative values. The highest encapsulation efficiencies were observed when Eudragit polymers took part in the composition of the polymeric matrix, compared with PCL and PLGA NP exhibiting low LMWH entrapment. The in vitro LMWH release in phosphate buffer from all formulations ranged from 10 to 25% and was more important (two- to threefold) when esterase was added into the dissolution medium. The in vitro biological activity of released LMWH, determined by the anti-factor Xa activity with a chromogenic substrate, was preserved after the encapsulation process, making these NP good candidates for oral administration.     

Preparation and Characterization of Heparin-Loaded Polymeric Microparticles

ABSTRACT

Microparticles containing heparin were prepared by a water-in-oil-in-water emulsification and evaporation process with pure or blends of biodegradable (poly-?-caprolactone and poly(d,l-lactic-co-glycolic acid)) and of positively-charged non-biodegradable (Eudragit® RS and RL) polymers. The influence of polymers and some excipients (gelatin A and B, NaCl) on the particle size, the morphology, the heparin encapsulation rate as well as the in vitro drug release was investigated. The diameter of the microparticles prepared with the various polymers ranged from 80 to 130 µm and was found to increase significantly with the addition of gelatin A into the internal aqueous phase. Microparticles prepared with Eudragit RS and RL exhibited higher drug entrapment efficiency (49 and 80% respectively), but lower drug release within 24 h (17 and 3.5% respectively) than those prepared with PCL and PLAGA. The use of blends of two polymers in the organic phase was found to modify the drug entrapment as well as the heparin release kinetics compared with microparticles prepared with a single polymer. In addition, microparticles prepared with gelatin A showed higher entrapment efficiency, but a significant initial burst effect was observed during the heparin release. The in vitro biological activity of heparin released from the formulations affording a suitable drug release has been tested by measuring the anti-Xa activity by a colorimetric assay with a chromogenic substrate. The results confirmed that heparin remained unaltered after the entrapment process.     

Optimization of PLGA nanoparticles formulation containing L-DOPA by applying the central composite design

The aim of this work was to prepare L-DOPA loaded poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles by a modified water-in-oil-in-water (W₁/O/W₂) emulsification solvent evaporation method. A central composite design was applied for optimization of the formulation parameters and for studying the effects of three independent variables: PLGA concentration, polyvinyl alcohol (PVA) concentration and organic solvent removal rate on the particle size and the entrapment efficiency (response variables). Second-order models were obtained to adequately describe the influence of the independent variables on the selected responses. The analysis of variance showed that the three independent variables had significant effects (p < 0.05) on the responses. The experimental results were in perfect accordance with the predictions estimated by the models. Using the desirability approach and overlay contour plots, the optimal preparation area can be highlighted. It was found that the optimum values of the responses could be obtained at higher concentration of PLGA (5%, w/v) and PVA (6%, w/v); and faster organic solvent removal rate (700 rpm). The corresponding particle size was 256.2 nm and the entrapment efficiency was 62.19%. FTIR investigation confirmed that the L-DOPA and PLGA polymer maintained its backbone structure in the fabrication of nanoparticles. The scanning electron microscopic images of nanoparticles showed that all particles had spherical shape with porous outer skin. The results suggested that PLGA nanoparticles might represent a promising formulation for brain delivery of L-DOPA. The preparation of L-DOPA loaded PLGA nanoparticles can be optimized by the central composite design.     

Protein functionalized tramadol-loaded PLGA nanoparticles: preparation,optimization, stability and pharmacodynamic studies

Poly (d,l-lactide-co-glycolide acid) (PLGA) Nanoparticles (NPs) with sustained drug release and enhanced circulation time presents widely explored non-invasive approach for drug delivery to brain. However, blood-brain barrier (BBB) limits the drug delivery to brain. This can be overcome by anchoring endogenous ligand like Transferrin (Tf) and Lactoferrin (Lf) on the surface of NPs, allowing efficient brain delivery via receptor-mediated endocytosis. The aim of the present investigation was preparation, optimization, characterization and comparative evaluation of targeting efficiency of Tf- vs. Lf-conjugated NPs. Tramadol-loaded PLGA NPs were prepared by nanoprecipitation techniques and optimized using 3³ factorial design. The effect of polymer concentration, stabilizer concentration and organic:aqueous phase ratio were evaluated on particle size (PS) and entrapment efficiency (EE). The formulation was optimized based on desirability for lower PS (<150 nm) and higher EE (>70%). Optimized PLGA NPs were conjugated with Tf and Lf, characterized and evaluated for stability study. Pharmacodynamic study was performed in rat after intravenous administration. The optimized formulation had 100 mg of PLGA, 1% polyvinyl alcohol (PVA) and 1:2 acetone:water ratio. The Lf and Tf conjugation to PLGA NPs was estimated to 186 Tf and 185 Lf molecules per NPs. Lyophilization was optimized at 1:2 ratio of NPs:trehalose. The NPs were found stable for 6 months at refrigerated condition. Pharmacodynamic study demonstrated enhanced efficacy of ligand-conjugated NPs against unconjugated NPs. Conjugated NPs demonstrated significantly higher pharmacological effect over a period of 24 h. Furthermore Lf functionalized NPs exhibited better antinociceptive effect as compared to Tf functionalized NPs.     

Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity

Objective: Saquinavir (SQV) is a US-FDA approved HIV protease inhibitor (HPI) for HIV cure. The purpose of the present investigation was to develop and characterize the anticancer potential of the SQV-loaded folic acid (FA) conjugated PEGylated and non-PEGylated poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs) (SQV–Fol–PEG–PLGA and SQV–Fol–PLGA) employing PC-3 (human prostate) and MCF-7 (human breast) cancer cell lines.

Materials and methods: Developed NPs were characterized by IR, NMR, DSC, XRD, size, charge and further tested for drug loading and cellular uptake properties.

Result: The entrapment efficiency was found to be 56?±?0.60 and 58?±?0.80 w/v for SQV–Fol–PEG–PLGA and SQV–PLGA NPs, respectively. The obtained results of SQV–Fol–PEG–PLGA showed enhanced cytotoxicity and cellular uptake and were most preferentially taken up by the cancerous cells via folate receptor-mediated endocytosis (RME) mechanism. At 260?µM concentration, SQV–PLGA NPs and SQV–Fol–PEG–PLGA NPs showed 20%, 20% and 23% cell growth inhibition in PC-3 cells, respectively whereas in MCF-7 cells it was 12%, 15% and 14% cell growth inhibition, respectively.

Conclusions: Developed targeted SQV–Fol–PEG–PLGA NPs were superior anticancer potential as compared to non-targeted SQV–PLGA NPs. Thus, these targeted NPs provide another option for anticancer drug delivery scientists.     

Paclitaxel-Loaded Microparticles for Intratumoral Administration via the TMT Technique: Preparation,Characterization, and Preliminary Antitumoral Evaluation

In our pursuit to develop suitable therapeutic particulate systems for intratumoral delivery by the targeted multi-therapy (TMT) technique, we describe the preparation of paclitaxel-loaded poly(d,l-lactic-co-glycolic) acid (PLGA) microparticles (MPs) (drug loading 35–38%, wt/wt; size 0.7–5 μm). Magnetite (15%, wt/wt) was also incorporated in some preparations for a future magnetic resonance imaging (MRI)-guided delivery. X-ray diffraction (XRD) and differential scanning calorimetry (DSC) experiments showed that paclitaxel was not encapsulated in its initial crystalline form. The paclitaxel in vitro release pattern showed a biphasic tendency with a burst effect followed by a sustained release (28% released amount after 1 month), which was accompanied with MP erosion and degradation signs as confirmed by scanning electronic microscopy (SEM) micrographs. The paclitaxel-loaded MPs demonstrated a dose-dependent antitumor effect on human uterine cancer cells, with an IC₅₀ value relatively close to that of commercial Taxol®. This paclitaxel delivery system represents a potent antiprofilerative and radiosensitizer agent for intratumoral administration via the TMT technique.     

Temperature and amino acid-assisted size- and morphology-controlled photochemical synthesis of silver decahedral nanoparticles

Stable silver decahedron nanoparticles were produced under the blue light irradiation (light-emitting diodes) of a modified precursor solution that has been previously reported. To improve the formation of the nano-decahedrons under blue light, we proposed the use of amino acids with electrically charged side chains (L-arginine, L-lysine and L-histidine). Our results show that L-arginine and L-lysine are best suited to improve the yield of the decahedrons. We also followed the kinetics of the photochemical synthesis under different irradiance conditions of 80, 50 and 15?mW/cm². The maximum irradiance, 80?mW/cm², resulted in a synthesis that was twice as fast as those associated with lower irradiances, and the corresponding decahedron yield was higher. The optimal temperature of the precursor solution for the improvement of the photochemical synthesis of silver decahedrons with Triton X-100 as a surfactant was also determined.     

SN-38 loading capacity of hydrophobic polymer blend nanoparticles: formulation,optimization and efficacy evaluation

One of the most important problems in nanoencapsulation of extremely hydrophobic drugs is poor drug loading due to rapid drug crystallization outside the polymer core. The effort to use nanoprecipitation, as a simple one-step procedure with good reproducibility and FDA approved polymers like Poly(lactic-co-glycolic acid) (PLGA) and Polycaprolactone (PCL), will only potentiate this issue. Considering that drug loading is one of the key defining characteristics, in this study we attempted to examine whether the nanoparticle (NP) core composed of two hydrophobic polymers will provide increased drug loading for 7-Ethyl-10-hydroxy-camptothecin (SN-38), relative to NPs prepared using individual polymers. D-optimal design was applied to optimize PLGA/PCL ratio in the polymer blend and the mode of addition of the amphiphilic copolymer Lutrol^®F127 in order to maximize SN-38 loading and obtain NPs with acceptable size for passive tumor targeting. Drug/polymer and polymer/polymer interaction analysis pointed to high degree of compatibility and miscibility among both hydrophobic polymers, providing core configuration with higher drug loading capacity. Toxicity studies outlined the biocompatibility of the blank NPs. Increased in vitro efficacy of drug-loaded NPs compared to the free drug was confirmed by growth inhibition studies using SW-480 cell line. Additionally, the optimized NP formulation showed very promising blood circulation profile with elimination half-time of 7.4?h.     

Hydrophobic amino acids grafted onto chitosan: a novel amphiphilic chitosan nanocarrier for hydrophobic drugs

Abstract

Objective: The objective of this study is to develop a novel biocompatible amphiphilic drug delivery for hydrophobic drugs, chitosan (CS) was grafted to a series of hydrophobic amino acids including l-alanine (A), l-proline (P), and l-tryptophan (W) by carbodiimide mediated coupling reaction.

Materials and methods: Chemical characteristics of the modified polymers were determined and confirmed by FT-IR, ¹H NMR, and UV–vis spectroscopy and the degree of substitution was quantified by elemental analysis. The modified polymers were used to form amphiphilic chitosan nanocarriers (ACNs) by the conventional self-assembly method using ultrasound technique. The morphology and the size of ACNs were analyzed by scanning electron microscope (SEM) and Dynamic light scattering (DLS).

Results and discussion: The sizes of spherical ACNs analyzed by SEM were obviously smaller than those of determined by DLS. The ACNs effectively surrounded the hydrophobic model drug, letrozole (LTZ), and demonstrated different encapsulation efficiencies (EE), loading capacities (LC), and controlled drug release profiles. The characteristics of ACNs and the mechanism of drug encapsulation were confirmed by molecular modeling method. The modeling of the structures of LTZ, profiles of A, P, and W grafted onto CS and the wrapping process around LTZ was performed by quantum mechanics (QM) methods. There was a good agreement between the experimental and theoretical results. The cell viability was also evaluated in two cell lines compared with free drug by MTT assay.

Conclusion: The hydrophobic portion effects on ACNs’ characteristics and the proper selection of amino acid demonstrate a promising potential for drug delivery vector.     

L-Histidine-modified biocompatible zinc oxide nanocrystals

In this article, we report a new method of preparing size-controlled and well-dispersed ZnO nanocrystals using L-histidine as the capping agent. The synthesis and properties of ZnO nanocrystals capped with L-histidine prepared by the wet chemical route are presented. The structural properties of L-histidine-capped nanocrystals are investigated by XRD, TEM, EDAX and FTIR spectroscopy. The optical characterisation of the nanocrystals is carried out on the basis of UV-Vis absorption and photoluminescence spectroscopy. The size of the L-histidine-capped ZnO nanocrystals is less than 10?nm as confirmed from TEM images. The elemental composition detected from EDAX establishes the presence of the capping agent in the samples. For L-histidine-modified ZnO nanocrystals, the UV absorption edge shifts towards the blue region compared to pure ZnO, suggesting the formation of nanocrystals of smaller size. The intense photoluminescence emission observed around 527?nm for L-histidine-capped ZnO offers high prospects in bio-imaging applications. The colloidal stability of the capped nanocrystals is very good as it remains stable without settling down for more than three weeks. Nanocrystals of different sizes have also been synthesised and their properties studied. The present synthesis route is of low cost and easy to control offering high purity to the products, using only bio-compatible materials. The functionalised nanoparticles are suitable for biological applications.     

Preliminary investigation on the design of biodegradable microparticles for ivermectin delivery: set up of formulation parameters

The aim was to design sterile biodegradable microparticulate drug delivery systems based on poly(dl-lactide) (PLA) and poly(?-caprolactone) (PCL) and containing ivermectin (IVM), an antiparasitic drug, for subcutaneous administration in dogs. The drug delivery system should: (i) ensure a full 12-month protection upon single dose administration; (ii) be safe with particular attention regarding IVM dosage and its release, in order to prevent over dosage side effects. This preliminary work involves: polymer selection, evaluation of the effects of γ-irradiation on the polymers and IVM, investigation and set up of suitable microparticle preparation process and parameters, IVM-loaded microparticles in vitro release evaluation.

Results of gel permeation chromatography analysis on the irradiated polymers and IVM mixtures showed that combination of IVM with the antioxidant α-tocopherol (TCP) reduces the damage extent induced by irradiation treatment, independently on the polymer type.

Solvent evaporation process was successfully used for the preparation of PLA microparticles and appropriately modified; it was recognized as suitable for the preparation of PCL microparticles. Good process yields were achieved ranging from 76.08% to 94.72%; encapsulation efficiency was between 85.76% and 91.25%, independently from the polymer used. The type of polymer and the consequent preparation process parameters affected microparticle size that was bigger for PCL microparticles (480–800?µm) and solvent residual that was >500?ppm for PLA microparticles. In vitro release test showed significantly faster IVM release rates from PCL microparticles, with respect to PLA microparticles, suggesting that a combination of the polymers could be used to obtain the suitable drug release rate.     

Design of a digit-serial multiplier over GF(2m) using a karatsuba algorithm

ABSTRACT

A Karatsuba algorithm (KA) is used for highly accurate multiplication using a divide and conquer approach. A new approach to a polynomial digit-serial multiplier that uses an optimal digit size (d) for KA decomposition has recently been proposed. In this study, the proposed architecture uses three small multipliers to derive an optimal digit size (d) for the case of trinomial based fields. Using the proposed KA decomposition, this study establishes five types of sub-quadratic multipliers, which are, the recombined m-bit exponentiation multipliers using a KA. The theoretical results show that the proposed polynomial exponentiation multipliers that use a KA have a value of (d × m)/2 and involve significantly less time and area complexity than existing digit-serial multipliers. The simulation results for the proposed method demonstrate a respective 68.20%, 77.37%, 72%, 83.18%, 36.66% decrease in area × time over GF(2³⁶), GF(2⁸⁴), GF(2¹²⁶), GF(2²⁰⁴) and GF(2³⁴⁰).     

Solubility and solution stability studies of different amino acid prodrugs of bromhexine

Objective: The aim of the present study was to prepare the amino acid prodrugs of bromhexine hydrochloride to improve its solubility.

Methods: All the prodrugs were synthesized by first reacting bromhexine with tert-butoxycarbonyl (Boc) protected amino acid and then deprotection was carried out by using trifluoroacetic acid. These prodrugs were characterized by their melting points, NMR, mass and FTIR spectroscopy. Solubility and partition coefficient of bromhexine and various prodrugs were determined. The solution stability of various prodrugs was also determined in various buffers of pH ranging from 2 to 10. Degradation rate constants and half-life were also determined at various pH.

Results and discussion: The structures of all the synthesized prodrugs were confirmed by NMR, mass and FTIR spectra. The prodrug 2-N-l-alanyl-bromhexine hydrochloride showed maximum solubility and minimum partition coefficient value. These prodrugs may hydrolyze by one or more mechanisms. The order of decreasing rates of hydrolysis was 2-N-l-prolyl-bromhexine hydrochloride > 2-N-glycyl-bromhexine hydrochloride > 2-N-l-alanyl-bromhexine hydrochloride. All the prodrugs exhibited maximum stability in the acidic pH range and undergo base catalyzed hydrolysis.

Conclusion: Solubility studies and partition coefficient values indicated that the synthesized prodrug, 2-N-l-alanyl-bromhexine hydrochloride, was least lipophilic as compared to other synthesized prodrugs. Solution stability studies showed that this prodrug undergo minimum hydrolysis at 37°C. So, it is concluded that 2-N-l-alanyl-bromhexine hydrochloride exhibits better solubility and stability as compared to other synthesized prodrugs.     

The Role of Several l-HPCs in Preventing Tablet Capping During Direct Compression of Metronidazole

Several low-hydroxypropyl cellulose (l-HPC) derivatives (LH-11, 21, 22, 31, and 32) differing in granulometric particle size or in hydroxypropyl content were considered in the present study. The l-HPC grades were characterized as pure powders, in order to determine both compression and densification behavior, in presence or in absence of magnesium stearate as lubricant, and then, were physically mixed in different proportions with metronidazole, which was also previously characterized as pure powder. The tabletability and compressibility of these binary mixtures were then evaluated, in presence or in absence magnesium stearate as lubricant at two different compression speeds (20 and 70 mm/sec). It was observed that both binary mixture compression behavior and capping tendency were influenced by compression speed and by the presence of lubricant.

Differences in anti-capping efficiency between the l-HPCs may be related to their hydroxypropyl content. This parameter influences the interaction between the metronidazole and the polymer particles, and consequently the ability of the binary system to undergo densification under compression.     

Viscoelastic interactions between polydeoxyribonucleotide and ophthalmic excipients

This study investigated the interaction between polydeoxyribonucleotide (PDRN) and several ionic and nonionic isotonic agents, thickeners and a preservative that were employed as excipients in ophthalmic preparations. Interaction of each individual excipient and PDRN aqueous solution was evaluated by analyzing their rheological properties. Rheological properties of PDRN solutions were evaluated by dynamic oscillatory shear tests and values of elastic modulus (G′), viscous modulus (G″) and loss tangent (tan δ) were used to assess the relative changes in viscoelastic properties. At given concentrations, sodium chloride was found to show alteration in viscoelastic properties of PDRN solution while nonionic isotonic agents like d-glucose and d-sorbitol did not alter them. Similarly, nonionic water soluble polymers like polyvinylpyrrolidone (PVP) and hydroxypropyl methylcellulose (HPMC) also did not interact with PDRN to alter the viscoelastic properties. However, there were changes observed when carbopol 940 was used as a thickener. Therefore, PDRN was found to interact with ionic excipients and the interactions were negligible when nonionic materials were examined, which suggests that nonionic excipients are suitable to be formulated with PDRN.     

An effective treatment approach of DPP-IV inhibitor encapsulated polymeric nanoparticles conjugated with anti-CD-4 mAb for type 1 diabetes

Nanotechnology based biomedical approaches and surface modification techniques made it easier for targeting specific site and improving the treatment efficacy. The present study reports on targeted polymeric nanoparticles conjugated with antibody as a site-specific carrier system for effective treatment of type 1 diabetes. Sitagliptin (SP)-loaded Poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NP) were prepared by nanoprecipitation cum solvent evaporation method and were characterized in terms of morphology, size, surface charge, and entrapment efficiency. Optimized batch demonstrated a particle size of 105.24?nm, with significant entrapment efficacy. In vitro release studies exhibited a controlled release pattern of 67.76?±?1.30% in 24?h, and a maximum of 96.59?±?1.26% at the end of 48?h. Thiol groups were introduced on the surface of SP-NPs whose concentration on SP-NPs was 27?±?2.6?mmol/mol PLGA-NPs, anti-CD4 antibody clone Q4120 was conjugated to the thiolated SP-NPs via a sulfo-MBS cross-linker, ～70% conjugation was observed. The in vitro cytotoxicity studies performed on RIN-5?F cells for mAb-SP-NPs presented an IC₅₀ of 76?µg/mL, and the insulin release assay had revealed an increased release at 5.15?±?0.16?IU/mL. The results indicate that mAb-SP-NPs allowed a controlled release of SP and thereby produced insulin levels comparable with control. Therefore, mAb-SP-NPs system appears to be effective in the treatment of auto immune diabetes, subject to further analysis.     

PLGA–PEG–PLGA hydrogel for ocular drug delivery of dexamethasone acetate

Aim: This study aims to investigate the suitability of thermosensitive triblock polymer poly-(dl-lactic acid-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–PLGA as a matrix material for ocular delivery of dexamethasone acetate (DXA). Methods: The copolymer was synthesized and evaluated for its thermosensitive and gelation properties. DXA in situ gel-forming solution based on PLGA–PEG–PLGA copolymer of 20% (w/w) was prepared and evaluated for ocular pharmacokinetics in rabbit according to the microdialysis method, which was compared to the normal eye drop. Result: The copolymer with 20% (w/w) had a low critical solution temperature of 32°C, which is close to the surface temperature of the eye. The C_max of DXA in the anterior chamber for the PLGA–PEG–PLGA solution was 125.2 μg/mL, which is sevenfold higher than that of the eye drop, along with greater area under the concentration–time curves (AUC). Conclusion: These results suggest that the PLGA–PEG–PLGA copolymer is potential thermosensitive in situ gel-forming material for ocular drug delivery, and it may improve the bioavailability, efficacy of some eye drugs.     

Sugars as solid dispersion carrier to improve solubility and dissolution of the BCS class II drug: clotrimazole

Solid dispersion of poorly soluble BCS class II drug, clotrimazole, was prepared with the aim of enhancing its dissolution profile. Solid dispersions were prepared using various sugars as carriers at different weight ratio to drug-like d-mannitol, d-fructose, d-dextrose and d-maltose by fusion method. The solubility of plain clotrimazole in different percent of sugar solutions was measured. Also, its solubility in solid dispersion and their physical mixture were assessed. The dissolution of all the prepared SD tablets, direct compressed clotrimazole tablet and plain drug were tested using the U.S. Pharmacopeia convention (USP) apparatus II. The dissolution profiles were characterized by parameters like area under curve (AUC), mean residence time (MRT), mean dissolution time (MDT) and percent dissolution efficiency (% DE). The release kinetics study was performed using DD Solver TM software. The selected solid dispersions (SDs) were evaluated for antifungal activity. A 100% solution of mannitol showed 806-fold increases in solubility as compared with plain clotrimazole in water. It was observed that the dissolution profile of clotrimazole was improved by mannitol SD at drug to sugar ration of 1:3. The percent DE value for mannitol SD tablet was found to be 77.3516% as against plain drug and directly compressed tablet of clotrimazole at 50.9439% and 31.33%, respectively. Also the antifungal activity indicated by inhibition zone was found to be 54?mm indicating enhance activity against Candida albicans as compared with plain CTZ at 6.6?mm. Thus, it can be concluded that the sugar alcohol, that is, mannitol is a more promising hydrophilic carrier for solid dispersion preparation to improve the solubility and dissolution of poorly soluble drugs.     

Preparation and characterization of heparin-loaded polymeric microparticles

Microparticles containing heparin were prepared by a water-in-oil-in-water emulsification and evaporation process with pure or blends of biodegradable (poly-epsilon-caprolactone and poly(D,L-lactic-co-glycolic acid)) and of positively-charged non-biodegradable (Eudragit RS and RL) polymers. The influence of polymers and some excipients (gelatin A and B, NaCl) on the particle size, the morphology, the heparin encapsulation rate as well as the in vitro drug release was investigated. The diameter of the microparticles prepared with the various polymers ranged from 80 to 130 microns and was found to increase significantly with the addition of gelatin A into the internal aqueous phase. Microparticles prepared with Eudragit RS and RL exhibited higher drug entrapment efficiency (49 and 80% respectively) but lower drug release within 24 h (17 and 3.5% respectively) than those prepared with PCL and PLAGA. The use of blends of two polymers in the organic phase was found to modify the drug entrapment as well as the heparin release kinetics compared with microparticles prepared with a single polymer. In addition, microparticles prepared with gelatin A showed higher entrapment efficiency, but a significant initial burst effect was observed during the heparin release. The in vitro biological activity of heparin released from the formulations affording a suitable drug release has been tested by measuring the anti-Xa activity by a colorimetric assay with a chromogenic substrate. The results confirmed that heparin remained unaltered after the entrapment process.     

VLSI floorplan repair using dynamic white-space management,constraint graphs,and linear programming

In VLSI layout, floorplanning refers to the task of placing macrocells on a chip without overlap while minimizing design objectives such as timing, congestion, and wire length. Experienced VLSI designers have traditionally been able to produce more efficient floorplans than automated methods. However, with the increasing complexity of modern circuits, manual design flows have become infeasible. An efficient top-down strategy for overlap removal which repairs overlaps in floorplans produced by placement algorithms or rough floorplanning methodologies is presented in this article. The algorithmic framework proposed incorporates a novel geometric shifting technique coupled with topological constraint graphs and linear programming within a top-down flow. The effectiveness of this framework is quantified across a broad range of floorplans produced by multiple tools. The method succeeds in producing valid placements in almost all cases; moreover, compared with leading methods, it requires only one-fifth of the run-time and produces placements with 4–13% less wire length and up to 43% less cell movement.